
    
      The drug being tested in this survey is called alogliptin and metformin hydrochloride
      combination tablet. This tablet is being tested to treat people who have type 2 diabetes
      mellitus with renal impairment (mild), hepatic impairment (mild or moderate), or advanced age
      (65 years and more).

      This survey is an observational (non-interventional) study and will look at the long-term
      safety and efficacy of the alogliptin and metformin hydrochloride combination tablet in the
      routine clinical setting. The planned number of observed patients will be approximately 600.

      This multi-center observational trial will be conducted in Japan.
    
  